Form 4: Spero Therapeutics Director Scott Thomas Jackson Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Scott Thomas Jackson reports acquisition and disposal of Spero Therapeutics stock, including the grant of restricted stock units.
Summary
- On May 29, 2024, Scott Thomas Jackson, a director of Spero Therapeutics, reported changes in beneficial ownership of the company's stock.
- Jackson acquired 20,000 shares of common stock through restricted stock units (RSUs) at a price of $0.00.
- These RSUs vest on May 29, 2025, contingent upon Jackson's continued service.
- Following these transactions, Jackson beneficially owns 55,000 shares of Spero Therapeutics stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the holdings of a key company director.
Stakeholder Impact
- The change in beneficial ownership may be of interest to shareholders, as it reflects the director's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: Acquisition of 20,000 shares of common stock through restricted stock units. |
| 05/29/2025 | Vesting date for the 20,000 restricted stock units. |
| 05/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.